After months of debate and uncertainty, the World Health Organization has released a proposal for naming biosimilars, which are designed to emulate brand-name biologics and are forecast to save untold billions of dollars in health care costs in coming years. At issue is whether biosimilars should be given the same International Proprietary Name, or INN, as brand-name biologics. The global INN system is overseen by the WHO, which has held several meetings to resolve the question. And a key point of contention is whether different INNs would hamper substitution needed for lowering health care costs, and this has divided the pharmaceutical industry.
Hey, check out all the research scientist jobs. Post your resume today!
